RBFC
KNSA icon

Roman Butler Fullerton & Co’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Roman Butler Fullerton & Co’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$408K Buy
6,700
+848
+14% +$44K 0.1% 204
2026
Q1 		$275K Sell
5,852
-536
-8% -$23.7K 0.08% 234
2025
Q4 		$271K Buy
6,388
+1,000
+19% +$40.1K 0.07% 232
2025
Q3 		$201K Buy
+5,388
New +$175K 0.05% 256

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Roman Butler Fullerton & Co's KNSA Position: Q2 2026 in Review

Roman Butler Fullerton & Co increased its Kiniksa Pharmaceuticals (KNSA) stake by 14% in Q2 2026, buying an estimated $44K and bringing the position to 6,700 shares worth $408K. The position accounts for 0.1% of the portfolio, ranked #204.

Roman Butler Fullerton & Co first reported a position in KNSA in Q3 2025 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Roman Butler Fullerton & Co held 6,700 shares of Kiniksa Pharmaceuticals worth $408K as of Q2 2026.
  • Roman Butler Fullerton & Co bought 848 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $44K.
  • Kiniksa Pharmaceuticals made up 0.1% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #204 holding.
  • Roman Butler Fullerton & Co first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.